Precision Medicine in Lung Cancer: Optimizing Care for HER2 (ERBB2) Mutations - CME - Guideline Central

CME

Title
Precision Medicine in Lung Cancer: Optimizing Care for HER2 (ERBB2) Mutations
Link
Description
HER2 mutations in metastatic NSCLC may be uncommon, but missing them can mean missing a critical treatment opportunity. In this activity, you’ll uncover how HER2 (ERBB2) alterations drive tumor growth and why they’re linked to poorer outcomes and brain metastases. Learn how to apply next-generation sequencing (NGS) to identify eligible patients and interpret results that guide targeted therapy decisions. Explore emerging treatments, including HER2-directed agents, and how they reshape care for this subset of patients. Real-world insights will help you bridge the gap between testing and treatment. If you’re treating lung cancer, this is one biomarker you can’t afford to overlook.
Target Audience
This educational activity is intended for oncology clinicians (MD/DOs, NP/PAs, and nurses), with a secondary target audience that includes pathology and pulmonary clinicians (MD/DOs, NP/PAs, and nurses).
Learning Objectives
  • Describe the epidemiology, molecular features, and clinical relevance of HER2 (ERBB2) mutations in mNSCLC, and differentiate them from other common oncogenic drivers
  • Apply evidence-based guidelines for molecular testing in mNSCLC and interpret HER2 (ERBB2) mutation results from NGS reports using best practices
  • Evaluate current and emerging therapies for HER2 (ERBB2)-mutant mNSCLC, with emphasis on agents targeting tyrosine kinase domain activating mutations
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Oncology
Keywords
lung cancer
Disclosures and Disclaimers
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
Accredited Providers
  • The France Foundation
Commercial Support
  • Boehringer Ingelheim Pharmaceuticals, Inc
Activity Expiration Date
April 29, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
Nursing1 Contact HoursANCC - American Nurses Credentialing Center
AAPA Category 1 Credit1 CreditsAAPA- American Academy of Physician Associates
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.